One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!

PHIO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.77%

Insider Buying (Last 12 Months): $11,355.00

Insider Selling (Last 12 Months): $0.00

Phio Pharmaceuticals Insider Trading History Chart

Phio Pharmaceuticals Share Price & Price History

^$0.68

▼ -0.026 (-3.68%)

As of 04/26/2024 11:52 AM ET

Days: 30 | 90 | 365

Claim Your Complimentary Bitcoin Reward

From Crypto Swap Profits | Ad

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

Phio Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/26/2024	Robert J Bitterman	CEO	Buy	2,500	$0.91	$2,275.00	18,990
6/30/2023	Robert J Bitterman	CEO	Buy	1,000	$2.88	$2,880.00	18,211
6/14/2023	Robert L Ferrara	Director	Buy	2,000	$3.10	$6,200.00	6,000
12/14/2022	Robert J Bitterman	Chairman	Buy	2,000	$0.39	$780.00	74,541
12/7/2022	Robert J Bitterman	Chairman	Buy	2,000	$0.39	$780.00	72,541
11/29/2022	Robert J Bitterman	Chairman	Buy	215	$0.40	$86.00	68,541
11/25/2022	Robert J Bitterman	Chairman	Buy	2,500	$0.42	$1,050.00	68,326
11/23/2022	Robert L Ferrara	Director	Buy	2,000	$0.41	$820.00	25,000
11/16/2022	Robert J Bitterman	Chairman	Buy	1	$1,750.00	$1,750.00	1
8/16/2021	Gerrit Dispersyn	CEO	Buy	6,000	$1.63	$9,780.00

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.

SEC Filings (Institutional Ownership Changes) for Phio Pharmaceuticals (NASDAQ:PHIO)

57.31% of Phio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Phio Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/14/2023	Anson Funds Management LP	22,571	$65K	0.0%	N/A	1.505%
8/10/2023	Cetera Investment Advisers	10,666	$31K	0.0%	N/A	0.711%
8/2/2023	Bank of Montreal Can	10,000	$38K	0.0%	N/A	0.667%
8/11/2022	Cetera Investment Advisers	75,000	$53K	0.0%	-16.7%	0.549%
11/16/2021	Cetera Investment Advisers	30,000	$61K	0.0%	N/A	0.222%
11/9/2021	BlackRock Inc.	35,592	$72K	0.0%	-17.8%	0.263%
9/17/2021	Virtu Financial LLC	27,110	$61K	0.0%	+74.7%	0.200%
8/13/2021	Vanguard Group Inc.	276,561	$0.63M	0.0%	+125.4%	2.043%
8/12/2021	Dimensional Fund Advisors LP	23,960	$54K	0.0%	-31.2%	0.177%
5/19/2021	Virtu Financial LLC	15,522	$42K	0.0%	N/A	0.115%
5/14/2021	Dimensional Fund Advisors LP	34,808	$93K	0.0%	+38.3%	0.257%
5/12/2021	Geode Capital Management LLC	87,501	$0.23M	0.0%	+330.6%	0.647%
5/10/2021	GSA Capital Partners LLP	132,333	$0.36M	0.1%	+30.5%	0.978%
3/26/2021	Susquehanna International Group LLP	12,058	$32K	0.0%	N/A	0.085%
3/8/2021	Dimensional Fund Advisors LP	25,177	$68K	0.0%	N/A	0.178%
2/25/2021	Dimensional Fund Advisors LP	25,177	$68K	0.0%	N/A	0.178%
2/4/2021	GSA Capital Partners LLP	101,401	$0.27M	0.0%	+376.6%	1.754%
12/11/2020	Virtu Financial LLC	35,929	$77K	0.0%	N/A	0.622%
11/6/2020	GSA Capital Partners LLP	21,278	$46K	0.0%	N/A	0.368%
7/16/2020	Wedbush Securities Inc.	33,374	$73K	0.0%	N/A	0.577%
5/15/2020	Sabby Management LLC	255,194	$0.45M	0.2%	N/A	8.901%
5/12/2020	JPMorgan Chase & Co.	21,681	$38K	0.0%	N/A	0.755%

Data available starting January 2016

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Today's Range

Now: $0.68

$0.67

$0.70

50 Day Range

MA: $0.80

$0.64

$1.08

52 Week Range

Now: $0.68

$0.50

$6.85

Volume

6,643 shs

Average Volume

364,780 shs

Market Capitalization

$3.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Who are the company insiders with the largest holdings of Phio Pharmaceuticals?: Phio Pharmaceuticals' top insider shareholders include:
Robert J Bitterman (Chairman)
Robert L Ferrara (Director)
Robert J Bitterman (CEO)
Learn More about top insider investors at Phio Pharmaceuticals.

The World's First "$20 Trillion Drug?"

From Behind the Markets | Ad

Get the name of the stock here >>>